In patients with ischemic stroke, NVAF, and ASCVD, adding an antiplatelet to OAC therapy did not affect net clinical benefit at 2 y

Authors

Institutions

Publication Details

Journal
Annals of Internal Medicine
Published
2026-02-01
DOI
https://doi.org/10.7326/annals-25-05308-jc
Primary Topic
Acute Ischemic Stroke Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In patients with ischemic stroke, NVAF, and ASCVD, adding an antiplatelet to OAC therapy did not affect net clinical benefit at 2 y

Abhilekh Srivastava, Mukul Sharma
Annals of Internal Medicine
Acute Ischemic Stroke Management
article

In patients with ischemic stroke, NVAF, and ASCVD, adding an antiplatelet to OAC therapy did not affect net clinical benefit at 2 y

Abhilekh Srivastava, Mukul Sharma
article en

Abstract

No abstract available for this paper.
Annals of Internal MedicineVol. 179(2)
McMaster University (CA)
Openalex Percentile: Top 68%
Acute Ischemic Stroke Management
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

In patients with ischemic stroke, NVAF, and ASCVD, adding an antiplatelet to OAC therapy did not affect net clinical benefit at 2 y — Abhilekh Srivastava, Mukul Sharma · Annals of Internal Medicine (2026) | TGRS Research Map | TGRS